Organigram (OGI) Competitors $1.48 +0.03 (+2.07%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends OGI vs. ORIC, ANAB, STOK, OCS, TRML, IMNM, CDXC, IGMS, ABVX, and HUMAShould you be buying Organigram stock or one of its competitors? The main competitors of Organigram include ORIC Pharmaceuticals (ORIC), AnaptysBio (ANAB), Stoke Therapeutics (STOK), Oculis (OCS), Tourmaline Bio (TRML), Immunome (IMNM), ChromaDex (CDXC), IGM Biosciences (IGMS), ABIVAX Société Anonyme (ABVX), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Organigram vs. ORIC Pharmaceuticals AnaptysBio Stoke Therapeutics Oculis Tourmaline Bio Immunome ChromaDex IGM Biosciences ABIVAX Société Anonyme Humacyte ORIC Pharmaceuticals (NASDAQ:ORIC) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends. Does the media refer more to ORIC or OGI? In the previous week, ORIC Pharmaceuticals had 9 more articles in the media than Organigram. MarketBeat recorded 10 mentions for ORIC Pharmaceuticals and 1 mentions for Organigram. Organigram's average media sentiment score of 0.00 beat ORIC Pharmaceuticals' score of -0.34 indicating that Organigram is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ORIC Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Organigram 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in ORIC or OGI? 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.6% of Organigram shares are owned by institutional investors. 5.6% of ORIC Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable earnings and valuation, ORIC or OGI? ORIC Pharmaceuticals has higher earnings, but lower revenue than Organigram. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioORIC PharmaceuticalsN/AN/A-$100.70M-$1.80-4.86Organigram$120.01M1.34-$184.34M-$0.42-3.52 Which has more volatility and risk, ORIC or OGI? ORIC Pharmaceuticals has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Does the MarketBeat Community believe in ORIC or OGI? Organigram received 136 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 72.09% of users gave ORIC Pharmaceuticals an outperform vote while only 70.71% of users gave Organigram an outperform vote. CompanyUnderperformOutperformORIC PharmaceuticalsOutperform Votes6272.09% Underperform Votes2427.91% OrganigramOutperform Votes19870.71% Underperform Votes8229.29% Do analysts rate ORIC or OGI? ORIC Pharmaceuticals currently has a consensus target price of $18.29, suggesting a potential upside of 109.22%. Given ORIC Pharmaceuticals' higher possible upside, equities research analysts plainly believe ORIC Pharmaceuticals is more favorable than Organigram.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ORIC or OGI more profitable? ORIC Pharmaceuticals has a net margin of 0.00% compared to Organigram's net margin of -45.57%. Organigram's return on equity of -16.76% beat ORIC Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ORIC PharmaceuticalsN/A -42.47% -38.86% Organigram -45.57%-16.76%-14.32% SummaryORIC Pharmaceuticals beats Organigram on 9 of the 16 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Organigram News Delivered to You Automatically Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGI vs. The Competition Export to ExcelMetricOrganigramPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.93M$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio-3.524.8389.0213.30Price / Sales1.34372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book0.607.876.085.74Net Income-$184.34M$153.61M$119.07M$225.93M7 Day Performance-1.33%-2.00%-1.84%-1.32%1 Month Performance-15.91%-7.47%-3.65%0.60%1 Year Performance20.33%31.80%31.62%26.23% Organigram Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGIOrganigram0.469 of 5 stars$1.48+2.1%N/A+16.5%$157.93M$120.01M-3.52860ORICORIC Pharmaceuticals4.1871 of 5 stars$8.74-1.7%$18.29+109.2%+22.4%$627.34MN/A0.0080Analyst RevisionANABAnaptysBio2.486 of 5 stars$20.31+1.7%$54.64+169.0%+40.0%$618.03M$17.16M-3.28100STOKStoke Therapeutics3.8396 of 5 stars$11.31-2.6%$20.83+84.2%+171.2%$614.95M$8.78M0.00100OCSOculis2.6709 of 5 stars$14.91-0.7%$29.20+95.8%+55.3%$608.37M$980,000.000.002TRMLTourmaline Bio1.8572 of 5 stars$24.00+2.1%$65.00+170.8%+36.0%$602.60MN/A0.0044IMNMImmunome1.5384 of 5 stars$9.33-0.6%$28.83+209.0%+19.8%$586.09M$14.02M0.0040Analyst RevisionCDXCChromaDex3.8229 of 5 stars$7.50-0.3%$8.00+6.7%+417.2%$572.85M$83.57M735.74106Analyst DowngradeIGMSIGM Biosciences4.7018 of 5 stars$9.77+2.4%$16.13+65.1%+63.3%$567.29M$2.13M0.00190ABVXABIVAX Société Anonyme2.9963 of 5 stars$8.86-0.6%$39.80+349.2%-19.6%$560.79MN/A0.0061HUMAHumacyte2.8803 of 5 stars$4.41-0.2%$11.00+149.4%+71.6%$555.04M$1.57M-3.29150Insider Trade Related Companies and Tools Related Companies ORIC Competitors ANAB Competitors STOK Competitors OCS Competitors TRML Competitors IMNM Competitors CDXC Competitors IGMS Competitors ABVX Competitors HUMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OGI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organigram Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organigram With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
